Skip to Navigation Skip to Search Skip to Content
Search All Centers

PARP Inhibitors in BRCA-Mutated Breast Cancer

Read Transcript

Published on September 24, 2017

PARP inhibitors are an effective therapeutic option for BRCA-mutated ovarian cancer patients, but how do they stack up against BRCA-mutated breast cancer? Dr. Giuseppe Curigliano, Co-Chair of the Division of Medical Oncology at European Institute of Oncology (EIO), Clinician and Researcher specializing in breast cancer, highlights the results of a study presented at ESMO 2017 about PARP inhibitors used in this patient population.

 This interview was recorded at the European Society of Medical Oncology (ESMO) congress held in Madrid (September 2017). Breast cancer videos recorded at ESMO 17 are part of an educational program by the Patient Empowerment Foundation (PEF). We thank Roche for their support.

Featuring

Your site is AWESOME! Thank you all so much for this incredible resource to families who are in crisis/affected by cancer.

— Loyal Patient Power viewer

You might also like

Transcript |

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Dr. Curigliano:

They are used up to now for ovarian cancer patients. The data from the OlympiA that had been updated at the meeting are positive. So if you use a PARP inhibitor versus chemotherapy, you get much more benefit in terms of response rate and progression-free survival, but the approval is still pending and we hope also for BRCA-mutated we can use this new class of agents.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.